SLC5A2 and Alzheimer disease: Notably, a 2020 study conducted by Hierro-Bujalance et al. delved into the impact of empagliflozin, a representative drug from the SGLT2 inhibitor group, on vascular damage and impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes.